Anifrolumab in systemic lupus erythematosus: a profile of its use

Anifrolumab (Saphnelo™), an intravenously administered immunoglobulin G1 kappa monoclonal antibody targeting the type 1 interferon alpha receptor, is effective and generally well tolerated as add-on to standard therapy in adults with moderate severe systemic lupus erythematosus (SLE). reduces overall disease activity patients SLE despite receiving stable standard-of-care treatment, based on totality of evidence from randomized, double-blind, placebo-controlled, phase 2b 3 clinical trials. also has corticosteroid-sparing effects skin severity. Therapeutic benefits anifrolumab appear be sustained over longer-term treatment. With respect tolerability, recipients are at increased risk infections (including herpes zoster). Additional long-term data being collected ongoing extension Systemic (SLE) a chronic autoimmune affecting multiple parts body, common areas including joints. While aetiology complex yet fully understood, dysregulation (IFN) system involved development. (Saphnelo™) that acts antagonist IFN receptor. In various countries worldwide, intravenous approved SLE. these patients, helps reduce activity, severity need for oral corticosteroids. Adverse events typically mild intensity most commonly such colds. well-tolerated treatment option therapy.